Bedrijfsoverzicht
Phathom Pharmaceuticals, Inc. is a biopharmaceutical entity dedicated to the development and commercialization of therapeutic treatments specifically targeting gastrointestinal diseases within the United States market. The company operates within the broader Healthcare sector and functions specifically in the Biotechnology industry, a classification that signifies its reliance on research and development to bring novel medical solutions to patients. Currently, the organization employs a workforce of 371 individuals and holds a market capitalization of $1.00B, while reporting trailing twelve-month (TTM) revenue of $175.11M. These valuation and revenue figures position Phathom as a mid-cap biotechnology firm with a significant revenue base for its stage, indicating a company that has moved beyond initial discovery into active commercialization phases with VOQUEZNA, which has completed Phase III clinical trials for erosive gastroesophageal reflux disease.
Financiële gezondheid
The company reported a revenue of $175.11M for the trailing twelve months, yet this figure is contrasted sharply by a net income of $-221,247,008 and an EBITDA of $-159,352,992, revealing a substantial gap between top-line sales and bottom-line profitability that points to significant operational expenses or research costs consuming the majority of generated revenue. This financial structure results in a free cash flow of $-107,858,128, indicating that the company is burning cash at a rate that requires external funding or cash reserves to sustain operations in the near term. Profitability metrics further illustrate this financial reality, with a gross margin of 87.1% showing high efficiency in production, but an operating margin of -10.3% and a profit margin of -126.3% demonstrating that overhead costs and losses severely impact the bottom line. The balance sheet reflects a total cash position of $129.97M against total debt of $589.17M, a disparity that highlights a leveraged capital structure where liabilities significantly exceed liquid assets. While the debt-to-equity ratio is listed as N/A due to the equity constraints, the current ratio stands at 1.73, suggesting that the company possesses sufficient current assets to cover its short-term liabilities, providing a buffer for liquidity needs. Return on Equity is marked as N/A, while Return on Assets sits at -31.4%, metrics that collectively reveal that management is currently utilizing the company's asset base to generate negative returns, a common characteristic for biotechnology firms in heavy investment phases before product approvals generate sustained profitability.
Waarderingsbeoordeling
Valuation metrics for Phathom present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of 8.18, a divergence that implies the market expects earnings to turn positive in the future despite current losses. The price-to-book ratio is reported at -2.06, a negative figure that indicates the company's market value is below its book value, often seen in biotech stocks where intangible assets and future pipeline potential outweigh current asset valuations. Alternative valuation measures such as a price-to-sales ratio of 5.73 and an EV/EBITDA of -9.13 suggest that the stock is priced based on sales multiples rather than traditional earnings power, reflecting the high-risk, high-reward nature of the asset class. Price action over the last year has seen the stock trade between a 52-week low of $2.21 and a 52-week high of $18.31, placing the current valuation within a wide historical range that underscores the volatility typical of small-cap biotechnology companies. The stock exhibits a beta of 0.61, which indicates that its price volatility is lower than the broader market, suggesting that the stock may move less dramatically than large-cap indices despite its smaller market capitalization.
Growth & Income
Revenue growth for the company is robust, with year-over-year revenue growth reaching 94.1%, while earnings growth is listed as N/A due to the absence of positive earnings to compound. The absence of positive earnings growth relative to revenue expansion implies that the company is prioritizing rapid sales scaling and market penetration over immediate profit generation, a strategy typical for companies launching new indications like VOQUEZNA. As a non-dividend payer, the company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash flows are retained within the business to fund research, development, and commercialization efforts. This reinvestment strategy aligns with the company's growth profile, where the primary objective is to expand the commercial footprint of its gastrointestinal treatments rather than providing income to shareholders.